Most voltage-gated K+ (VGK) channels oppose cell excitation by shaping and terminating action potentials. Dominant, gain-of-function (gf) mutations in the
egl-2 VGK channel cause defective excitation of egg-laying and enteric muscles. These defects are fully rescued by tricyclic antidepressants. Consistent with the enteric muscle phenotype of
egl-2(gf), an
egl-2::gfp fusion is expressed in the intestinal muscles.
egl-2::gfp is also expressed in the chemosensory neuron AWC and in the anterior touch neuron ALM, and
egl-2(gf) mutants are defective in AWC-mediated chemotaxis to iso-amyl alchohol and in response to anterior touch. We find that like the muscle excitation defects, these neuronal defects are rescued by tricyclic antidepressants, and that this rescue is reversible upon removal of the drug. We conclude that expression of
egl-2(gf) in excitable cells causes cell inactivation that is rescued by tricyclics. Both
egl-2(gf) mutations cause a change in a sixth transmembrane domain alanine that is conserved in all VGK channels. To assess the physiological consequences of the gf mutation, we made the gf change in the mouse
egl-2 homolog m-eag, and expressed both wild-type and mutant cDNAs in Xenopus oocytes. Preliminary results indicate that, compared to the wild type, the mutant channel accelerates channel activation and shifts voltage dependence to more negative potentials. Expression in vivo of the mutant channel would be expected to hyperpolarize an excitable cell, consistent with the excitation-defective phenotypes of
egl-2(gf) mutants. We are currently generating transgenic mice carrying m-eag(gf) fused to the mouse growth hormone promoter to test for reversible inactivation of the growth hormone-releasing neurosecretory cells.